Interview of Allergan's CEO David E.I. Pyott indicates the mainstreaming of aesthetics is core to Allergan's growth strategy and overall industry expansion

Q: The concept of mainstreaming aesthetic treatments has been discussed extensively by industry analysts and journalists.What does this really mean in terms of procedure volume statistics and the potential for market growth?

A: We believe the growth we’re seeing is being driven not only by the aging of the baby boomer generation but also by growing demand among all age groups – and across social and economic demographics – for safe and effective approaches to maintaining a healthy and youthful appearance and self-image. While the market has grown substantially over the past ten years – with sales for non-surgical aesthetic procedures increasing by nearly 750% and consumers spending more than $12 billion on cosmetic procedures in 2006 in the U.S. alone*, we believe it is still largely an untapped and young market with enormous growth potential. As part of this growth, it is our intention to mainstream the use of our products, among those considering, while harnessing the unique benefits and innovation associated with Allergan’s brand offerings.

As just one example, the number of dermal filler procedures performed in the U.S. is still just about half the number recorded in Europe, which we believe was due, in part, to the limited choice of available collagen and hyaluronic acid dermal filler products and limited investment in truly expanding this particular segment of the market. We estimate that once JUVÉDERM entered the U.S. market in 2007, market growth accelerated from about 15% to 50%. In this and other areas, Allergan is committing substantial resources – in R&D, physician education and consumer awareness, sales and marketing, strategic acquisition or partnership – to continue to fuel market growth.

Source: Allergan CEO Shares Vision for Future of Medical Aesthetic Industry